Indo Us Biotech LimitedQ1 FY27 Results & Financial Update
Indo Us Biotech Limited: Q1 FY27 standalone results and company financials – revenue ₹32.99 Cr, PAT ₹3.04 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Indo Us Biotech price & chart
Market price₹73.54
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Indo Us Biotech Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Indo Us Biotech Limited reported a standalone revenue from operations of INR 32.99 crore for the quarter ended 30 June 2026, accompanied by total income of INR 33.11 crore.
Profitability for the quarter remained positive, with profit before tax (PBT) standing at INR 3.08 crore and profit after tax (PAT) registering at INR 3.04 crore.
Basic and diluted earnings per share (EPS) for the standalone entity came in at INR 1.51 for the period.
Total expenses for the quarter were well-contained relative to income generation, allowing the company to record a net profit margin of approximately 9.21% based on total operating revenue.
Finance costs for the quarter were reported at INR 0.74 crore, reflecting ongoing capital servicing requirements, while depreciation and amortization expenses stood at INR 0.27 crore.
Tax expense for the period was modest at INR 0.04 crore, contributing to the conversion of operating performance into bottom-line earnings.
Other income contributed INR 0.12 crore to the total income pool during the quarter, supplementing core operational inflows.
During the first quarter of fiscal year 2027, ending 30 June 2026, Indo Us Biotech recorded standalone revenue from operations of INR 32.99 crore, underpinned by active seasonal demand for agricultural seeds.
01 · Business model
What does Indo Us Biotech do?
Indo Us Biotech Limited operates in the agricultural biotechnology and seed production sector, focusing on the research, development, processing, and marketing of high-yielding crop seeds and agricultural inputs.
The company's primary business model revolves around plant breeding, seed multiplication, and distribution of diverse field and vegetable crop seeds designed to meet the productivity requirements of farming communities.
Revenues are generated primarily through the commercial sale of seeds across domestic agricultural markets, supported by an established distribution network and dealer relationships.
The operational structure relies heavily on seasonal agricultural cycles, seed processing infrastructure, and continuous investments in agricultural R&D to maintain varietal performance and disease resistance.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹32.99 Cr |
| Total income | ₹33.11 Cr |
| Profit before tax | ₹3.08 Cr |
| Profit after tax | ₹3.04 Cr |
| EPS | ₹1.51 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 9.2% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 9.3% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.12 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Generated INR 32.99 crore in operational revenue during Q1 FY27 from commercial seed distribution and agricultural product lines.
Contributed INR 0.12 crore in other income, bringing total quarterly income to INR 33.11 crore.
What drove margins
Incurred finance costs of 0.74 crore during the quarter, impacting overall pre-tax earnings.
Reported a low tax expense of INR 0.04 crore for the quarter, supporting the net profit margin of 9.21%.
The company incurred a minimal tax expense of INR 0.04 crore during the quarter, supporting the conversion of PBT of INR 3.08 crore into a net profit of INR 3.04 crore.
Operations absorbed finance costs of INR 0.74 crore and depreciation of INR 0.27 crore, reflecting the servicing of debt and capital asset wear during the quarter.
04 · Reported developments
What changed operationally
Maintained positive profitability with a PAT of INR 3.04 crore and an EPS of INR 1.51 for the standalone quarter.
05 · Beyond the numbers
What changed beyond the numbers
Reported update
Standalone Filing Compliance
The financial results for Q1 FY27 were submitted as a standalone filing through official exchange-structured XBRL reporting channels on 12 August 2026.
06 · Key Q&A
The quarter, answered directly
What does Indo Us Biotech do?
Indo Us Biotech Limited operates in the agricultural biotechnology and seed production sector, focusing on the research, development, processing, and marketing of high-yielding crop seeds and agricultural inputs.
What is the clearest takeaway from Q1 FY27?
Indo Us Biotech Limited reported a standalone revenue from operations of INR 32.99 crore for the quarter ended 30 June 2026, accompanied by total income of INR 33.11 crore.
What drove revenue or demand?
Generated INR 32.99 crore in operational revenue during Q1 FY27 from commercial seed distribution and agricultural product lines.
What mattered most for margins or profitability?
Incurred finance costs of 0.74 crore during the quarter, impacting overall pre-tax earnings.
What changed operationally beyond the headline numbers?
The financial results for Q1 FY27 were submitted as a standalone filing through official exchange-structured XBRL reporting channels on 12 August 2026.
What should the next disclosure help confirm?
Monitor upcoming quarterly financial filings to track sequential revenue progression and seasonal demand patterns.
07 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
08 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Financial Disclosures: Monitor upcoming quarterly financial filings to track sequential revenue progression and seasonal demand patterns.
- 02
Sequential Financial Tracking: Monitor subsequent quarterly filings to observe operational scaling and margin trends across upcoming agricultural crop seasons.
- 03
Cost Structure Evolution: Track the progression of finance costs and depreciation relative to top-line growth in future financial reports.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.